ATNM

Actinium Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.520

+0.090(+6.290%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

1.520

Open

1.430

VWAP

1.43

Vol

517.21K

Mkt Cap

46.79M

Low

1.350

Amount

738.99K

EV/EBITDA(TTM)

Total Shares

29.78M

-32.33M

EV/OCF(TTM)

P/S(TTM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. The Company develops and markets medicines for relapsed or refractory cancer patients who are treated primarily in large quaternary care hospitals and their catchment areas. Its Iomab-B and Actimab-A product candidates fill the major unmet medical needs in relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B is a targeted bridging therapy that provides both disease control and conditioning in one agent. Actimab-A is a targeted therapy for fit patients that has demonstrated an impressive extension in survival in a proof-of-concept study and is poised for advanced development in collaboration with the National Cancer Institute (NCI).

3 Analyst Rating

294.74% Upside

Wall Street analysts forecast ATNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATNM is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

294.74% Upside

Current: 1.520

Low

4.00

Averages

6.00

High

9.00

294.74% Upside

Current: 1.520

Low

4.00

Averages

6.00

High

9.00

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-04-28

New

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-04-28

New

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-04-01

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-04-01

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-27

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-27

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-25

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-25

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-20

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-20

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-18

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-18

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Actinium Pharmaceuticals Inc (ATNM.A) is -1.20, compared to its 5-year average forward P/E of -5.58. For a more detailed relative valuation and DCF analysis to assess Actinium Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.58

Current PE

-1.20

Overvalued PE

-2.82

Undervalued PE

-8.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.27

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.33

Undervalued EV/EBITDA

-4.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

223.83

Current PS

0.00

Overvalued PS

658.86

Undervalued PS

-211.20

Financials

Annual

Quarterly

FY2024Q4

YoY :

-100.00%

0.00

Total Revenue

FY2024Q4

YoY :

-27.44%

-7.51M

Operating Profit

FY2024Q4

YoY :

-28.66%

-6.65M

Net Income after Tax

FY2024Q4

YoY :

-38.24%

-0.21

EPS - Diluted

FY2024Q4

YoY :

-23.22%

-5.75M

Free Cash Flow

FY2024Q4

YoY :

-100.00%

N/A

Gross Profit Margin - %

FY2024Q4

YoY :

-100.00%

N/A

FCF Margin - %

FY2024Q4

YoY :

-100.00%

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ATNM News & Events

Events Timeline

2025-04-28 (ET)

2025-04-28

08:35:57

Actinium Pharmaceuticals' ATNM-400 shows efficacy in prostate cancer study

2025-04-28

08:05:39

Actinium's Actimab-A shows antileukemic activity in AML models

2025-03-27 (ET)

2025-03-27

08:51:11

Actinium announces positive ATNM-400 results in prostate cancer

News

9.0

04-28Newsfilter

PinnedActinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

7.0

07:25 AMPRnewswire

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

7.0

04-29PRnewswire

ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline